An incretin portfolio refers to a group of medications that mimic or enhance the action of incretin hormones, such as GLP-1 and GIP, to manage blood sugar. It includes drugs like semaglutide and tirzepatide, used primarily for type 2 diabetes and weight management. Patients seeking improved glycemic control and significant weight loss benefit most from this approach.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends